PLoS Medicine's Advisory Group on Publication Ethics by 
PLoS Medicine  |  www.plosmedicine.org 0201
Editorial
February 2007  |  Volume 4  |  Issue 2  |  e81
I
n March 2005, we announced 
the appointment of an external 
advisory committee “to advise us 
on individual cases for which we are 
concerned about competing interests 
or broader ethical questions” [1]. 
Two years on, what has the committee 
achieved and how has it helped to 
shape policies at the journal?
The committee is a “virtual” one, 
with seven members in two countries—
the United States and South Africa. 
When the PLoS Medicine editors have 
a case that presents us with an ethical 
dilemma, we submit anonymized details 
to the committee and ask for its advice. 
Committee members were chosen for 
their very broad expertise, not just in 
medical ethics but also in law, health 
policy, medical journalism and editing, 
clinical medicine, and clinical research. 
In response to our request for advice, 
the committee members share their 
opinions via a listserv, and then the 
committee chair presents a summary of 
the committee’s advice to the editors.
Since the committee was appointed, 
it has responded to ten queries. These 
queries can be divided into three broad 
themes: (1) competing interests; (2) 
preserving patient anonymity; and (3) 
the borderline between a research 
paper and a programmatic description.
Competing Interests
From its very ﬁ  rst issue, PLoS Medicine 
asked all authors to declare any 
competing interests (http:⁄⁄journals.
plos.org/plosmedicine/competing.
php), which we placed prominently 
alongside the authors’ biographical 
information. Initially we allowed 
authors to acknowledge their funding 
sources at the end of the article. This 
policy meant that some authors would 
declare that “no competing interests 
exist,” and yet in the funding statement 
at the end of their article would state 
that they had received funding from 
pharmaceutical companies. 
We presented examples of such 
cases to the committee, which was 
unanimous in believing that authors 
are poor judges of what constitutes 
a competing interest and that we 
should revise our policy. We therefore 
implemented the committee’s 
recommendations to: (1) make 
sure that competing interests and 
funding sources were declared 
together at the beginning of every 
article, and (2) ask authors to state 
what role the funder played in the 
submission and preparation of the 
article. Our policy regarding articles 
submitted spontaneously (rather than 
commissioned) for the Magazine 
section goes even further. If authors 
proposing a topic have competing 
interests that could reasonably be 
perceived as affecting their ability to 
write an objective Magazine piece, we 
will decline their article.
We were also concerned that 
some of our research papers had the 
potential to be “spun” favorably by drug 
companies, since these papers showed 
the beneﬁ  t of a particular blockbuster 
drug. In all cases, we as editors—
together with the academic editor and 
independent peer reviewers—were 
convinced that the studies were 
rigorous and should be published, 
but we wondered, “What can we do 
to reduce the risk of the results being 
‘spun’?” 
The committee’s overall opinion 
was reﬂ  ected by one member, who 
wrote: “If you think the article is sound 
enough to publish, you should publish 
it. You can’t control the spin, but you 
can make sure that full information 
(on author connections, ﬁ  nancial ties, 
etc) is available in the press release. 
Hopefully, this will prompt journalists 
to ask relevant questions.” 
In response to this advice, we have—
where appropriate—added information 
about authors’ competing interests 
within the press release. Unfortunately, 
research on media reports about 
blockbuster drugs has shown that 
journalists do poorly at reporting 
authors’ competing interests [2,3]. 
And so even if we add these interests 
to our press releases we recognize 
that journalists may not report them, 
but we will continue to encourage 
transparency as best as we can. 
Preserving Patient Anonymity
PLoS Medicine adheres to the principle 
that a case report that arises from 
the conﬁ  dential doctor–patient 
relationship cannot be published 
unless the patient (or family) has 
given written consent. But sometimes 
authors say that they are simply unable 
to obtain consent (for example, the 
patient has moved to a different 
country) and they offer to anonymize 
the report. If there are educational 
beneﬁ  ts in publishing such a report, 
and these beneﬁ  ts outweigh the risks 
of harm (for example, patients identify 
themselves and feel that their privacy 
has been violated), would it be ethically 
acceptable to publish the report 
without patient consent?
This question arose when we were 
approached by a legal organization that 
has amassed a wealth of illuminating 
medico-legal cases that could 
potentially educate doctors on how 
to stay out of court. Many of the cases 
involve patients who were harmed 
or died as a result of medical errors. 
We asked the organization if it had 
obtained consent from the patient or 
relatives to publish case details. It had 
not—but the organization promised 
to anonymize all patient details. “We 
feel the beneﬁ  ts of educating doctors 
about medical error outweigh any 
ethical concerns about the invasion 
of an individual’s privacy,” wrote a 
representative of the organization. 
“We take great care to anonymise the 
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cases in such a way that we feel it is 
extremely unlikely that anyone could 
be identiﬁ  ed by the narrative.”
Our advisory committee was 
unanimous in believing that 
anonymization would not be sufﬁ  cient 
to protect patient anonymity. As one 
committee member said, we could 
never be sure that the organization had 
done a thorough enough job of the 
anonymization process, and therefore, 
“we should assume there is a chance that 
the patient’s privacy will be violated,” 
with a risk of causing harm. As a result 
of the committee’s advice, we declined 
to publish these medico-legal cases.
Several of the questions that we put 
to the committee were related to the 
ethics of publishing “stock” photos 
of patients (these usually come from 
news agencies) in Magazine articles 
when we did not have the patient’s 
written consent. Most medical journals 
get around this problem by adopting 
a position of “assumed consent.” The 
BMJ, for example, justiﬁ  es publishing 
such photos as follows: “We believe that 
the BMJ would be at a disadvantage 
among other media if we didn’t use 
such images, and pictures can often 
tell a story more powerfully than words. 
But we cannot take responsibility for 
the consent of people who are shown 
in pictures that we have obtained 
from agencies, libraries, other 
publications, and other commercial 
sources…we assume that they and 
their photographers have obtained 
relevant permission from models in any 
images showing people” [4]. We asked 
our committee: should PLoS Medicine 
also assume consent to use photos of 
patients from news agencies in our 
Magazine articles?
The committee’s deliberations 
centered on a crucial difference 
between the BMJ and PLoS Medicine. 
Unlike the BMJ, we publish all 
materials under the Creative Commons 
Attribution License (http:⁄⁄journals.
plos.org/plosmedicine/license.php), 
which allows anyone to reuse the 
materials for any legal purpose. While 
the patients in the photos might have 
given consent to the news agency for 
their photo to be taken (and this is 
only an assumption), they certainly did 
not consent to the Creative Commons 
licensing agreement. And so the 
committee felt strongly that we should 
not use such photos, a position we have 
adopted.
Is a Program Description a 
Research Paper?
The most recent—and most 
contentious—ethical dilemma that we 
have faced concerned a paper that fell 
in the grey area between research and a 
programmatic description. The authors 
wished to describe their experience of 
delivering an innovative health care 
program under extremely difﬁ  cult 
conditions. The authors made no 
mention of Institutional Review Board 
(IRB) approval, and so we asked the 
committee whether it considered this 
sort of paper as a “study” that required 
prior IRB approval.
The committee was divided on 
this question. Some committee 
members felt that describing a health 
intervention in order to educate 
readers does not constitute research 
and so does not need IRB approval. 
“We don’t hold educational programs 
to this standard, nor do we hold 
government programs,” wrote one 
committee member, adding that “this 
seems to be to be a serious case of IRB 
creep” and suggesting that we were 
on a slippery slope to requiring “IRB 
approval even to publish a poem.” 
But other members felt strongly that 
as soon as an author is using patient 
data, there is a requirement for IRB 
approval. One member wrote that 
publishing a program description 
is “analogous to secondary data 
analyses—where data are collected from 
individuals for one purpose, but then 
used by researchers for another. In this 
case, it is still necessary to safeguard the 
individuals who provide the data.” 
Given the array of differing opinions 
from the committee, in the ﬁ  rst 
instance we asked for some additional 
clariﬁ  cations from the authors as to: 
(1) whether they sought IRB approval; 
(2) if they did not seek such approval, 
what was their rationale; and (3) 
whether in fact an IRB had conﬁ  rmed 
that no approval was necessary for a 
programmatic description. 
The authors explained that they had 
not sought prior IRB approval because 
they considered the paper to be “purely 
descriptive: no hypotheses have been 
tested; no speciﬁ  c data collection 
or analyses have been performed 
for research purposes, nor have any 
interviews or surveys been undertaken.” 
All the data in their paper, they said, 
“are derived from routine programme 
reporting and come from patient ﬁ  les 
completed by the doctor at the time of 
consultation.”
In response to our queries, the 
authors also asked their IRB to 
consider the question of whether this 
paper constituted research and, as 
such, whether it required post hoc 
ethical approval. The IRB wrote: “The 
contents of this paper are retrospective 
and descriptive and do not qualify 
as research as per the commonly 
understood meaning of this term.” 
We were satisﬁ  ed by these 
clariﬁ  cations from the authors and 
their IRB, and we plan to publish the 
paper. We have asked the authors to 
include a discussion of these ethical 
issues within the paper itself.
Conclusion
We believe that the external advisory 
committee has provided a valuable 
service, guiding, educating, and 
helping us to set policies that we hope 
have made the journal more “ethically 
robust.” We have particularly valued 
the fact that the different committee 
members bring such a diversity of views, 
and that the committee is able to give 
very rapid advice. We would like to 
thank the committee members, who 
are listed in Table S2 of reference [1], 
and we look forward to our ongoing 
collaboration.  
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